Page 45 - 2021_09-Haematologica-web

Monitoring of clonal evolution of AML
Contributions
EO collected samples, performed experiments, analyzed and interpreted data, and wrote the manuscript; IR analyzed and inter- preted data; LM, GC-T, XG, MG, JS interpreted data; PM col- lected samples and clinical data; RA and JML designed and super- vised research and experiments, analyzed and interpreted data, and wrote the manuscript; all authors prepared the report and approved the final version.
Acknowledgments
The study was conducted according to the Declaration of
Helsinki; the protocol was reviewed and approved by the Institutional Review Board/Independent Ethics Committe of the par- ticipating centers.
Funding
This study was supported by the Subdirección General de Investigación Sanitaria (Instituto de Salud Carlos III, Spain) grants PI13/02387 and PI16/01530, and the CRIS against Cancer foun- dation, grant 2014/0120. ML holds a postdoctoral fellowship of the Spanish Ministry of Economy and Competitiveness (FPDI-2013- 16409).
References
1. Kuehn EW, Walz G, Benzing T. Von hippel- lindau: a tumor suppressor links micro- tubules to ciliogenesis and cancer develop- ment. Cancer Res. 2007;67(10):4537-4540.
2. Klco JM, Miller CA, Griffith M, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015; 314(8):811-822.
3. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23(9):1969-1978.
4. Pemmaraju N, Kantarjian H, Garcia-Manero G, et al. Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience. Am J Hematol. 2015;90(1):27-30.
5. Bose P, Vachhani P, Cortes JE. Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat Options Oncol. 2017; 18(3):17.
6. Vosberg S, Greif PA. Clonal evolution of acute myeloid leukemia from diagnosis to relapse. Genes Chromosomes Cancer. 2019;58(12):839-849.
7. De S, Ganesan S. Looking beyond drivers and passengers in cancer genome sequenc- ing data. Ann Oncol. 2017;28(5):938-945.
8. Barber LJ, Davies MN, Gerlinger M. Dissecting cancer evolution at the macro- heterogeneity and micro-heterogeneity scale. Curr Opin Genet Dev. 2015;30:1-6.
9. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evo- lution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883-892.
10. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264-278.
11. Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-2487.
12. Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127(1):29-41.
13. Ramos NR, Mo CC, Karp JE, Hourigan CS. Current approaches in the treatment of relapsed and refractory acute myeloid leukemia. J Clin Med. 2015;4(4):665-695.
14. Cocciardi S, Dolnik A, Kapp-Schwoerer S, et al. Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nat Commun. 2019;10(1):2031.
15. McNeer NA, Philip J, Geiger H, et al. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia. 2019; 33(8): 1934-1943.
16.Onecha E, Linares M, Rapado I, et al. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia. Haematologica. 2019;104(2):288-296.
17. Cedena MT, Rapado I, Santos-Lozano A, et al. Mutations in the DNA methylation path- way and number of driver mutations predict response to azacitidine in myelodysplastic syndromes. Oncotarget. 2017;8(63):106948- 106961.
18. Gorello P, Cazzaniga G, Alberti F, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia. 2006;20(6):1103-1108.
19. Burge C, Karlin S. Prediction of complete gene structures in human genomic DNA. J Mol Biol. 1997;268(1):78-94.
20. Rubio-Camarillo M, Lopez-Fernandez H, Gomez-Lopez G, et al. RUbioSeq+: a multi- platform application that executes paral- lelized pipelines to analyse next-generation sequencing data. Comput Methods Programs Biomed. 2017;138:73-81.
21. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treat- ment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642-4649.
22. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommenda- tions from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
23. Christen F, Hoyer K, Yoshida K, et al. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood. 2019;133(10):1140-1151.
24. Jones JR, Weinhold N, Ashby C, et al. Clonal evolution in myeloma: the impact of main- tenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica. 2019; 104(7):1440-1450.
25. Walter RB, Othus M, Burnett AK, et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia. 2015; 29(2):312- 320.
26. Rothenberg-Thurley M, Amler S, Goerlich D, et al. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia. 2018;32(7):1598-1608.
27. Shlush LI. Age-related clonal hematopoiesis. Blood. 2018;131(5):496-504.
28. Bejar R. What biologic factors predict for transformation to AML? Best Pract Res Clin Haematol. 2018;31(4):341-345.
29. Metzeler KH, Herold T, Rothenberg-Thurley M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128(5):686-698.
30. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regula- tors and persist in remission. Proc Natl Acad Sci U S A. 2014;111(7):2548-2553.
31. Sottoriva A, Kang H, Ma Z, et al. A Big Bang model of human colorectal tumor growth. Nat Genet. 2015;47(3):209-216.
32. Jan M, Majeti R. Clonal evolution of acute leukemia genomes. Oncogene. 2013; 32(2):135-140.
33. Kronke J, Bullinger L, Teleanu V, et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood. 2013; 122(1):100- 108.
34. Jaiswal S, Fontanillas P, Flannick J, et al. Age- related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-2498.
35.Klco JM, Spencer DH, Miller CA, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell. 2014;25(3):379-392.
36. Quek L, Ferguson P, Metzner M, et al. Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. Blood Adv. 2016;1(3):193-204.
37. Shimizu H, Yokohama A, Ishizaki T, et al. Clonal evolution detected with convention- al cytogenetic analysis is a potent prognostic factor in adult patients with relapsed AML. Hematol Oncol. 2018;36(1):252-257.
38. Marcucci G, Mrozek K, Ruppert AS, et al. Abnormal cytogenetics at date of morpho- logic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. J Clin Oncol. 2004;22(12):2410- 2418.
39. Chen Y, Cortes J, Estrov Z, et al. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic signifi- cance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol. 2011;29(18):2507-2513.
40. Derman BA, Larson RA. Post-remission ther- apy in acute myeloid leukemia: Are we ready for an individualized approach? Best Pract Res Clin Haematol. 2019;32(4): 101102.
haematologica | 2021; 106(9)
2333